RetinalGenix Technologies, Inc. Signs Laboratory Lease Agreement With Life Science Incubator MBC BioLabs

RetinalGenix Technologies, Inc. has announced a new laboratory lease agreement with MBC BioLabs, a life science incubator, for a facility in San Carlos, California. The lease includes an option for Mission BioCapital, an affiliate of MBC BioLabs, to potentially invest in RetinalGenix. The company plans to use this fully equipped laboratory space to further develop its RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform, which focuses on genetic profiling and personalized medicine.

The lab is equipped with advanced scientific equipment, such as incubators, centrifuges, freeze dryers, and mass spectrometers, to support RetinalGenix's research initiatives. It is also located near Charles River Laboratories’ vivarium facility, which will assist in advancing in vivo animal research studies. In addition to the development of its genetic mapping platform, RetinalGenix is working on repurposing previously commercialized drugs for new treatments in dementia, parkinsonism, and macular degeneration. 

The company holds patents for repurposing drugs that have been on the market for over 30 years, now being re-evaluated through advanced genetic profiling. RetinalGenix is in discussions for a potential collaboration with Dr. Anatoly Dritschilo, Co-founder, Chairman of the Board, and Chief Science Officer of Shuttle Pharmaceuticals. Dr. Dritschilo is an expert in radiation oncology and molecular radiation biology, and his work has advanced therapeutic strategies that integrate molecular and radiation-based cancer treatments.

Jerry Katzman, MD, Chairman, President, and CEO of RetinalGenix, stated, “We are thrilled to join the prestigious cohort of leading-edge bio companies at MBC Biolabs. This opportunity will allow us to accelerate our mission to repurpose FDA-approved therapeutics for new indications, and to explore therapies targeting other ocular and neurodegenerative diseases.”

“RetinalGenix intends to expand Institutional Review Board (IRB) approval of a clinical study to include multiple practices. The facility at MBCBiolab is the perfect laboratory to accelerate the development of our RetinalGenix DNA/GPS™ platform,” commented Dr. Larry Perich, director of the current Florida-based study.

Fred Chasalow, Ph.D., Special Consultant for Therapeutics at RetinalGenix, will direct the company's laboratory activities. Dr. Chasalow, known for discovering three novel steroids, also serves on the Medical Advisory Board of DNA-GPS™, a division of RetinalGenix. He is currently researching novel neurohormones under a CDMRP grant, a program funded by the Department of Defense to support biomedical research. This new facility is a significant step for RetinalGenix as it continues to advance its research and drug repurposing efforts, with the goal of improving treatments for various neurodegenerative and ophthalmic conditions.